Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 3/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | GPR183 | P32249 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31315858 | 0.86 | ALDH1A1 (0.65) | LMNAGLATSHRHTTALDH1A1 | |
| SCHEMBL9344505 | 0.86 | ALDH1A1 (0.65) | LMNAGLATSHRHTTALDH1A1 | |
| SCHEMBL2112295 | 0.82 | USP2 (0.76) | LMNAGLATSHRHTTALDH1A1 | |
| SCHEMBL2113354 | 0.82 | USP2 (0.69) | LMNAGLATSHRHTTALDH1A1 | |
| SCHEMBL4009699 | 0.81 | L3MBTL1 (0.63) | L3MBTL1LMNAHTTALDH1A1USP2 | |
| SCHEMBL3824011 | 0.81 | MAPT (0.69) | LMNAGLATSHRHTTALDH1A1 | |
| SCHEMBL5306092 | 0.81 | MAPT (0.69) | L3MBTL1LMNAHTTALDH1A1 | |
| SCHEMBL18410347 | 0.81 | LMNA (0.87) | L3MBTL1LMNATSHRHTTALDH1A1 | |
| SCHEMBL14501975 | 0.81 | USP2 (0.80) | L3MBTL1LMNAHTTALDH1A1USP2 | |
| SCHEMBL709027 | 0.81 | USP2 (0.80) | L3MBTL1LMNAHTTALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | L3MBTL1 4124/4885LMNA 1057/4885GLA 4101/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | L3MBTL1 2776/4885LMNA 1917/4885GLA 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.